Rucaparib was cytotoxic to human cancer cell lines with mutated BRCA1/2 and was then found to be effective in a wide range of ovarian cancer cell lines (including homologous recombination pathway deficiencies not including BRCA1/2 mutations) alone and in combination with other agents [31,32]. This evidence concerns the gene BRCA1 and ovarian carcinoma.